JP2015528020A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528020A5
JP2015528020A5 JP2015525512A JP2015525512A JP2015528020A5 JP 2015528020 A5 JP2015528020 A5 JP 2015528020A5 JP 2015525512 A JP2015525512 A JP 2015525512A JP 2015525512 A JP2015525512 A JP 2015525512A JP 2015528020 A5 JP2015528020 A5 JP 2015528020A5
Authority
JP
Japan
Prior art keywords
deuterium
compound according
compound
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528020A (ja
JP6261580B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/052721 external-priority patent/WO2014022390A1/en
Publication of JP2015528020A publication Critical patent/JP2015528020A/ja
Publication of JP2015528020A5 publication Critical patent/JP2015528020A5/ja
Application granted granted Critical
Publication of JP6261580B2 publication Critical patent/JP6261580B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525512A 2012-07-30 2013-07-30 重水素化イブルチニブ Expired - Fee Related JP6261580B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677307P 2012-07-30 2012-07-30
US61/677,307 2012-07-30
PCT/US2013/052721 WO2014022390A1 (en) 2012-07-30 2013-07-30 Deuterated ibrutinib

Publications (3)

Publication Number Publication Date
JP2015528020A JP2015528020A (ja) 2015-09-24
JP2015528020A5 true JP2015528020A5 (enExample) 2016-08-25
JP6261580B2 JP6261580B2 (ja) 2018-01-17

Family

ID=48917743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525512A Expired - Fee Related JP6261580B2 (ja) 2012-07-30 2013-07-30 重水素化イブルチニブ

Country Status (13)

Country Link
US (2) US9422295B2 (enExample)
EP (1) EP2882751B1 (enExample)
JP (1) JP6261580B2 (enExample)
KR (1) KR20150038486A (enExample)
CN (1) CN104507946A (enExample)
AU (1) AU2013296627C9 (enExample)
BR (1) BR112015001839A2 (enExample)
CA (1) CA2879400A1 (enExample)
EA (1) EA201590296A1 (enExample)
ES (1) ES2682043T3 (enExample)
IN (1) IN2015DN00598A (enExample)
MX (1) MX2015001246A (enExample)
WO (1) WO2014022390A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882751B1 (en) 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN103965201A (zh) * 2014-04-30 2014-08-06 淮海工学院 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法
CN104945404B (zh) * 2014-06-25 2018-09-14 广东东阳光药业有限公司 一种n-丙烯羰基哌啶衍生物的制备方法
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
WO2016127915A1 (zh) * 2015-02-12 2016-08-18 上海度德医药科技有限公司 伊布替尼的制备方法
WO2016132383A1 (en) * 2015-02-18 2016-08-25 Mylan Laboratories Limited Process for the preparation of ibrutinib
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016151438A1 (en) * 2015-03-20 2016-09-29 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
KR20250070139A (ko) * 2016-05-04 2025-05-20 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
EP3606524B1 (en) 2017-04-04 2021-12-01 Combiphos Catalysts, Inc. Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
CN112876484B (zh) * 2020-08-31 2022-06-28 绍兴舜邦医药科技有限公司 一种氘代依鲁替尼的制备方法
CN114105990A (zh) * 2020-08-31 2022-03-01 北京四环制药有限公司 一种伊布替尼的合成方法
CN112125913B (zh) * 2020-10-29 2024-07-19 瑞阳制药股份有限公司 高纯度伊布替尼的合成方法
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2024109676A1 (zh) * 2022-11-21 2024-05-30 天津征程医药科技有限公司 具有btk抑制作用的吡唑并嘧啶衍生物
CN118063429B (zh) * 2022-11-23 2025-02-25 天津瑞程健达医药科技有限公司 作为btk抑制剂的吡啶酰胺类化合物
CN118307541A (zh) * 2023-01-09 2024-07-09 天津济坤医药科技有限公司 氘代吡唑并嘧啶衍生物及其制备方法和药物组合物、结合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
DE10155018A1 (de) * 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
BRPI0617987A2 (pt) 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
WO2013118150A1 (en) 2012-02-08 2013-08-15 Council Of Scientific & Industrial Research "electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste"
EP2882751B1 (en) * 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib

Similar Documents

Publication Publication Date Title
JP2015528020A5 (enExample)
JP2014097964A5 (enExample)
JP2014515351A5 (enExample)
JP2013032389A5 (enExample)
BR112015001839A2 (pt) ibrutinibe deuterado
JP2015525207A5 (enExample)
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
GEP201706735B (en) Kinase inhibitors
JP2013537203A5 (enExample)
JP2013147496A5 (ja) 有機金属錯体
JP2013542261A5 (enExample)
PH12015500294A1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP2015522045A5 (enExample)
JP2011518833A5 (enExample)
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
JP2013100341A5 (enExample)
JP2017514910A5 (enExample)
JP2013102146A5 (ja) 化合物
MX2016002794A (es) Compuestos antiproliferativos.
JP2015520770A5 (enExample)
JP2012519182A5 (enExample)
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP2013147490A5 (ja) イリジウム錯体
MD4194B1 (en) Trinuclear coordinative compound tris{µ-¢3,5-dibromo-2-hydroxybenzylidene-4′-(pyridin-2-yl)-thiosemicarbazido(2-)]copper}hydrate, exhibiting antifungal activity against Candida albicans
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди